VLRX - Valeritas Holdings, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.25
+0.03 (+2.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.22
Open1.25
Bid1.20 x 900
Ask1.21 x 1000
Day's Range1.18 - 1.34
52 Week Range0.78 - 6.79
Volume424,517
Avg. Volume446,210
Market Cap31.071M
Beta (3Y Monthly)14.33
PE Ratio (TTM)N/A
EPS (TTM)-5.09
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.50
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Valeritas Announces That V-Go® Insulin Delivery Device Has Launched in Italy

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today V-Go has launched and is now available in Italy through its previously disclosed exclusive distribution agreement with Movi SpA (“Movi”). “We are happy to announce the V-Go Wearable Insulin Delivery device is now available in Italy for patients with type 2 diabetes,” said Valeritas CEO, John Timberlake.

  • GlobeNewswire3 days ago

    Valeritas Wins Fifth Consecutive Cardinal Health Supply Chain Excellence Award

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today it has been awarded a Cardinal Health Supply Chain Excellence Award for the fifth consecutive year. “Receiving the Cardinal Health Supply Chain Excellence Award for the fifth consecutive year demonstrates our strong commitment to our V-Go customers,” said John Timberlake, President and Chief Executive Officer of Valeritas. Cardinal Health is a global, integrated healthcare services and products company, providing customized solutions for hospitals, health systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide.

  • ACCESSWIRE4 days ago

    Valeritas Holdings Revenues Grow on Acceptance of V-Go for Insulin, Analyst Report

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Valeritas Holdings, Inc. (VLRX), a commercial-stage medical technology company focused on people with diabetes by developing and commercializing innovative technologies. Valeritas' flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots.

  • GlobeNewswire5 days ago

    Valeritas Expects to Report Record Revenue for Third Quarter 2018

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced preliminary financial results for the third quarter of 2018. On a preliminary basis, Valeritas expects to record revenue for the third quarter ended September 30, 2018 of approximately $6.9 million, up approximately 36% over the third quarter of 2017.

  • GlobeNewswire9 days ago

    Valeritas is a Contributing Supporter of the Interactive Insulin Workshop at MEDS East Summit

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced they are supporting interactive insulin workshops at the Metabolic & Endocrine Disease Summit (MEDS) in Orlando, Florida. This four-day summit is the second of two semiannual conferences designed to advance the education of nurse practitioners and physician assistants who treat people with metabolic and endocrine diseases. As with the MEDS Summit that took place in April in San Diego, Valeritas is helping to support the 3.5-hour interactive Insulin Workshop.

  • GlobeNewswire10 days ago

    Persistent Use of Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diabetes

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today the publication this week of a manuscript titled “Clinical and Economic Considerations Based on Persistency with a Novel Insulin Delivery Device versus Conventional Insulin Delivery in Patients with Type 2 Diabetes: A Retrospective Analysis” in Research and Social Administrative Pharmacy, an international, peer-reviewed journal. Insulin delivery options have advanced over the years, but questions remain regarding whether persistent use of these latest innovations offers benefits over the conventional insulin delivery (CID) methods of insulin pen devices or insulin syringes.

  • GlobeNewswire18 days ago

    Valeritas’ V-Go® Demonstrates Benefits Versus Multiple Daily Injections in Patients with Type 2 Diabetes

    BRIDGEWATER, N.J., Oct. 02, 2018 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, a simple,.

  • GlobeNewswire24 days ago

    Valeritas Begins Medical Device Registration Process in China for Its V-Go® Wearable Insulin Delivery Device

    As part of this process, Valeritas has signed an agreement with an international contract research organization (CRO), who has extensive experience in China, who will work directly with the China National Drug Administration (CNDA) to complete the necessary requirements to gain regulatory approval for V-Go in China.

  • GlobeNewswire2 months ago

    Valeritas Announces that V-Go® Insulin Delivery Device Has Launched in Australia

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, affordable, all-in-one insulin delivery option that is worn like a patch for patients with diabetes, today announced V-Go has launched and is now available in Australia through its previously disclosed exclusive distribution agreement with AMSL Diabetes. “We are pleased to announce V-Go Wearable Insulin Delivery device is now available for patients with type 2 diabetes in Australia,” said Valeritas CEO, John Timberlake.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of VLRX earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Valeritas Holdings Inc Earnings Call

  • GlobeNewswire2 months ago

    Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth

    BRIDGEWATER, N.J., Aug. 07, 2018-- Valeritas Holdings, Inc., a medical technology company and maker of V-Go ® Wearable Insulin Delivery device, a simple, affordable, all-in-one, insulin delivery option ...

  • ACCESSWIRE2 months ago

    Valeritas Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Valeritas Holdings, Inc. (NASDAQ: VLRX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...

  • GlobeNewswire2 months ago

    Valeritas Announces V-Go® Distribution Agreement in Czech Republic and Slovakia

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that its distribution partner in Austria and Germany, MED TRUST, has exercised the rights to promote, market, and sell V-Go to diabetes clinics and patients in the Czech Republic and Slovakia. “We are excited that our partner, MED TRUST, has decided to expand its original distribution agreement to also include the Czech Republic and Slovakia,” said Valeritas CEO John Timberlake.

  • GlobeNewswire3 months ago

    Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical Benefits in Patients with Uncontrolled Type 2 Diabetes Previously Treated with Multiple Daily Injections

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, announced today a poster titled “Use of V-Go® Wearable Insulin Delivery device by Advanced Practitioners Demonstrated Improved Clinical Benefits in Patients with Type 2 Diabetes Uncontrolled on Multiple Daily Injections of Insulin” will be unveiled today at the Metabolic & Endocrine Disease Summit (MEDS) conference in San Diego, California. The analysis showed that insulin-dependent patients with uncontrolled type 2 diabetes clinically benefited after switching to V-Go from multiple daily injections (MDI). “For many patients with type 2 diabetes, being able to adhere to an insulin regimen consisting of multiple daily injections is a real challenge as it can be burdensome to daily living and complex,” said Amanda Patricia Wakim, DNP, FNP-BC an endocrinology-focused nurse practitioner in Wheeling, West Virginia.

  • GlobeNewswire3 months ago

    Valeritas Announces that V-Go® Insulin Delivery is Now Available in New Zealand

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced V-Go is now available in New Zealand through its exclusive distribution agreement with NZMS Diabetes. “We are delighted to announce patients with type 2 diabetes in New Zealand now have access to V-Go® Wearable Insulin Delivery device,” said Valeritas CEO, John Timberlake.

  • ACCESSWIRE3 months ago

    Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks

    On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Valeritas Holdings Inc. (NASDAQ: VLRX).

  • GlobeNewswire3 months ago

    Valeritas, Makers of V-Go® Insulin Delivery, is a Contributing Supporter of the Interactive Insulin Workshop at Two MEDS Conferences

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device for patients with diabetes, today announced their support of the interactive insulin workshops at the upcoming Metabolic & Endocrine Disease Summit (MEDS) programs. The first conference runs August 1-4, 2018, in San Diego, CA, with the Insulin Workshop on Saturday, August 4.  It is followed by an Orlando, FL, summit from October 10-13, 2018.

  • GlobeNewswire3 months ago

    Valeritas to Report Second Quarter 2018 Results August 7, 2018

    BRIDGEWATER, N.J., July 24, 2018-- Valeritas Holdings, Inc., a medical technology company and maker of V-Go ® Wearable Insulin Delivery device--- a simple, all-in-one, wearable insulin delivery option ...

  • Benzinga4 months ago

    Valeritas Stock Should More Than Double, Oppenheimer Says

    Valeritas Holdings Inc (NASDAQ: VLRX ), a medical technology company known for its V-Go Wearable Insulin Delivery device , could more than double in value, according to Oppenheimer. The Analyst Oppenheimer's ...

  • ACCESSWIRE4 months ago

    Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities

    On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Valeritas Holdings Inc. (NASDAQ: VLRX), Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), and Glaukos Corp. (NYSE: GKOS).

  • ACCESSWIRE4 months ago

    Valeritas Holdings, New Study Results Pump Up V-Go Insulin Delivery Device

    NEW YORK, NY / ACCESSWIRE / June 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Valeritas Holdings, Inc. (VLRX) is a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. The company shares jumped this week after the company advised positive results from its ENABLE study, showing that patients who switched from insulin pens and syringes to the company's wearable V-Go insulin delivery device experienced improved blood glucose levels and lowered their daily insulin dose. The VLRX primary target market consists of the approximately 5.6 million patients with type 2 diabetes who currently take injectable insulin, of which up to 4.5 million may not be achieving their target blood glucose goal.

  • ACCESSWIRE5 months ago

    Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Valeritas Holdings, Inc. (NASDAQ: VLRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VLRX as the Company's latest news hit the wire. On May 18, 2018, the Company reported positive results from two new studies assessing its V-Go Wearable Insulin Delivery device, during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Valeritas Holdings.

  • ACCESSWIRE5 months ago

    Free Daily Technical Summary Reports on Valeritas and Three Other Medical Supplies Stocks

    Stock Research Monitor: ILMN, NXTM, and SIEN LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on VLRX sign up now at www.wallstequities.com/registration . For today, WallStEquities.com ...